Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
34.07
-0.09 (-0.26%)
At close: May 22, 2026, 4:00 PM EDT
34.00
-0.07 (-0.20%)
After-hours: May 22, 2026, 7:00 PM EDT
Teva Pharmaceutical Industries Employees
Teva Pharmaceutical Industries had 33,950 employees as of December 31, 2025. The number of employees decreased by 2,880 or -7.82% compared to the previous year.
Employees
33,950
Change (1Y)
-2,880
Growth (1Y)
-7.82%
Revenue / Employee
$511,016
Profits / Employee
$46,097
Market Cap
39.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33,950 | -2,880 | -7.82% |
| Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
| Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
| Dec 31, 2022 | 36,826 | -711 | -1.89% |
| Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
| Dec 31, 2020 | 40,216 | 177 | 0.44% |
| Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
| Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
| Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
| Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
| Dec 31, 2015 | 42,888 | -121 | -0.28% |
| Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
| Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
| Dec 31, 2012 | 45,948 | 194 | 0.42% |
| Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
| Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
| Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
| Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
| Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
| Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
| Dec 31, 2005 | 14,698 | 885 | 6.41% |
| Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
| Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
| Dec 31, 2002 | 9,577 | 591 | 6.58% |
| Dec 31, 2001 | 8,986 | 361 | 4.19% |
| Dec 31, 2000 | 8,625 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Alkermes | 2,050 |
| Neurocrine Biosciences | 2,000 |
TEVA News
- 3 days ago - Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749 - Nasdaq
- 4 days ago - TEVA Gains EMA Acceptance for New Schizophrenia Treatment - GuruFocus
- 4 days ago - Teva announces EMA acceptance of MAA for olanzapine long-acting injectable - TheFly
- 4 days ago - The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults - GlobeNewsWire
- 7 days ago - Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution - GlobeNewsWire
- 7 days ago - Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders - Nasdaq
- 7 days ago - Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact - GlobeNewsWire
- 9 days ago - Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd - GuruFocus